US FDA Contracting Update: From Rating Site Quality Maturity To Blocking COVID-19 Scams
Contracts in works also would help track APIs, promote gene therapy standards, improve drug compounding, help extend shelf lives for US stockpile products and improve budget execution.
You may also be interested in...
Global Benchmarking Data Offer Path To Improved Drug Manufacturing Quality
Prospective new participants in benchmarking study must share manufacturing plant data by 20 November to see how they measure on quality against industry peers.
US FDA Launches Quality Maturity Pilots That Reward High-Performing OTC, Rx Manufacturers
One pilot target domestic manufacturers of finished drugs and another foreign manufacturers of APIs. As an incentive to participate, companies assigned high scores will be accorded regulatory flexibility. Also, participants that disclose facility ratings could “benefit from a competitive advantage.”
US FDA Launches Quality Maturity Pilot Program That Rewards High-Performing Manufacturers
High ratings on factors like quality culture could yield post-approval change flexibility for participating drug product and API manufacturing facilities.